Quarterly ResultMay 13, 2026, 04:12 PM
Acrivon Advances ACR-368 Phase 2b Interim Analysis to H2 2026; Q1 Net Loss $19.0M
AI Summary
Acrivon Therapeutics reported Q1 2026 financial results and provided significant updates on its clinical oncology programs. The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for serous endometrial cancer arms in H2 2026, driven by accelerated enrollment. The ACR-2316 Phase 1/2 study is progressing towards its expansion phase, showing favorable tolerability and durable clinical activity in AP3-prioritized tumors. The company's cash, cash equivalents, and marketable securities of $97.7 million as of March 31, 2026, plus $7.3 million from subsequent equity financing, are expected to fund operations into Q3 2027.
Key Highlights
- ACR-368 Phase 2b interim analysis for serous endometrial cancer arms expected in H2 2026.
- ACR-368 showed a 52% confirmed overall response rate (cORR) in serous EC subjects (N=23).
- ACR-2316 Phase 1/2 study is advancing to expansion phase with favorable tolerability and durable clinical activity.
- Net loss for Q1 2026 was $19.0 million, compared to $19.7 million for Q1 2025.
- Research and development expenses were $15.2 million for Q1 2026.
- Cash, cash equivalents, and marketable securities totaled $97.7 million as of March 31, 2026.
- Cash runway, including $7.3 million from subsequent financing, extends into Q3 2027.